Background
Lung macrophages function as large recipients of iron (Fe) [
1‐
5]. By depositing ferruginous material inside their lysosomes potentially hazardous Fe becomes separated from reactive oxygen species (ROS) by intracellular antioxidative enzyme systems [
1‐
5]. Following the enzymatic digestion of degradable Fe-containing material (executed by lysosomal enzymes working at acidic pH), liberated Fe becomes re-utilized in different cellular processes that require this metal [
6,
7]. However, lysosomes are acidic (pH 4.5-5.5) and rich in reducing equivalents (
e.g., cysteine); thus, free or loosely bound lysosomal Fe will partly exist in a redox-active ferrous state (Fe
2+) [
8,
9]. If hydrogen peroxide (H
2O
2) escapes the protective shield of antioxidants, aggressive hydroxyl radicals (HO
·) or similarly reactive Fe-centered radicals may be generated inside lysosomes by Fenton-type chemistry (Fe
2+ + H
2O
2 → Fe
3+ + HO
- + HO
·) [
3‐
6,
10‐
12]. The ensuing oxidative damage on the lysosomal membranes, which leads to lysosomal membrane permeabilization (LMP) and the leakage of lysosomal Fe and hydrolytic enzymes in to the cytosol, may result in cell death [
3‐
6,
10‐
12]. The cytosolic enzymes caspase-3 and −9, which are regarded as key mediators of apoptosis, may then become activated [
13,
14]. If the cell death is extensive, the lung macrophages often fail to phagocytose all of the apoptotic cells, and the resulting post-apoptotic necrosis may promote inflammation and fibrosis [
10‐
12,
15‐
19].
The bronchiolitis obliterans syndrome (BOS) is a fibro-proliferative disease of poorly understood etiology that is characterized by an irreversible decline in allograft function due to fibrotic remodeling of small airways,
i.e. obliterative bronchiolitis (OB) [
20]. The macrolide antibiotic azithromycin (AZM) is a promising drug for the prevention of (BOS) [
21]. Recently, a randomized, double-blind, placebo-controlled study provided evidence that lung allograft recipients, who received a low-dose of AZM (250 mg three times per week) continuously from the time of the post-transplantation hospital discharge, demonstrate a significantly lower incidence of BOS over a 2-yr follow-up period (12.5% compared to 44.2% in those who received placebo) [
21]. Previous observations on chronic inflammatory lung disease support the idea that the protective effect of AZM on the airways is anti-inflammatory/immunomodulatory rather than antimicrobial [
22,
23]. AZM enters cells and lysosomes by nonionic diffusion [
24‐
26]. The molecule is amphiphilic bearing two basic functions with appropriately weak pKa values [8.1 for the endocyclic tertiary amine and 8.8 for the tertiary amine carried by one of the two sugar moieties (desosamine)] [
24‐
26]. Thus, AZM is a weak base and lysosomotropic,
i.e., AZM is protonated, trapped and concentrated up to > 1000-fold inside the acidic lysosomes [
24‐
26].
Previously, we have shown that weak bases may attenuate the reactivity of lysosomal Fe, which protects lysosomes and cells against oxidative challenge [
27‐
29]. This effect is achieved by the drug either
(i) similar to the radio-protective agent amifostine and the synthesized derivative of the antioxidant α-lipoamide, α-lipoic acid-PLUS, which work as Fe-chelators [
27,
28] by stably binding intra-lysosomal Fe, or
(ii) by raising the pH in the acidic vacuome, which blocks the uptake of Fe from the transferrin/transferrin-receptor complex in late endosomes and/or inhibits the enzymatic liberation of Fe from Fe-rich organic elements such as ferritin and worn-out mitochondria inside lysosomes [
29].
Building on this previous research, we tested and found for the first time that the lung macrophages (and their lysosomes) from lung transplant recipients without AZM treatment are more susceptible to an oxidant challenge than the lung macrophages that originate from healthy subjects. In contrast, oxidant-exposed macrophages from transplant recipients treated with AZM did not exhibit lysosomal damage and dead cells were few. Results from oxidant-challenged murine macrophage-like J774 cells indicate that the cytoprotective potency of AZM on a molar basis is much greater than that of a high-molecular-weight derivative of the Fe chelator desferrioxamine (H-DFO) or ammonium chloride (NH4Cl).
Discussion
To the best of our knowledge, the present study is the first to demonstrate that the lysosomes of lung macrophages from lung transplant recipients are more susceptible to oxidative stress than the lysosomes of lung macrophages originating from healthy humans. Oxidant challenge led to a concomitant and pronounced lung allograft macrophage deaths (Figure
1). In contrast, macrophages from transplant recipients with AZM survived oxidant challenge significantly better and their lysosomes were efficiently protected against oxidants (Figure
1). This was despite the fact that macrophages from transplant recipients with AZM contained significantly more Fe and less GSH (Table
2), which both favor a pro-oxidative state of these macrophages. This observation does, indeed, indicate a significant protection afforded by AZM on oxidatively stressed lysosomes and cells. The differences noticed regarding Fe and GSH between the two groups of lung transplant macrophages is probably explained by macrophages with AZM being retrieved from much older transplants. Rejection and infection, other reasonable causes behind a sensitization towards oxidants, were not detected in any of the two groups.
Lung macrophages may provide an efficient defense against Fe-catalyzed oxidative lung tissue damage by harboring potentially harmful Fe inside their lysosomes [
1‐
5]. Lung macrophages digest both organic Fe-containing elements, such as hemoglobin derived from red blood cells, and inorganic Fe-transporting particles,
e.g., silica [
10‐
12]. Thus, in studies of lung macrophages that were harvested from a patient with ongoing pulmonary bleeding, we observed a dramatic increase of H-ferritin, which efficiently protected lysosomes and cells that were excessively loaded with Fe against oxidative injury [
12]. H-ferritin is known to rapidly and copiously sequester reactive Fe [
35], thereby acting as a custodian against Fenton-type chemistry outside as well as inside the lysosomes [
4‐
6,
10‐
13]. The latter is possible because the ferritin molecule normally is never completely Fe-saturated and therefore temporarily binds the lysosomal Fe in an un-reactive state before being degraded [
4‐
6,
12,
13]. GSH contributes to the protection by scavenging free radicals in the cytosol and by working as an electron donor for glutathione peroxidases through which H
2O
2 is reduced to water [
4,
5,
10‐
13].
However, this defense system by the lung macrophages might be over-whelmed if the cells and lysosomes are exposed to excessive Fe [
10,
11]. In a case of pulmonary alveolar proteinosis, we have previously shown that extensive amounts of reactive lysosomal Fe made lysosomes prone to rupture upon an oxidant-challenge that resulted in pronounced lung macrophage death [
11]. This scenario might also explain the response to oxidant challenge observed in the present study in cultures of macrophages from lung transplant recipients without AZM (Figure
1). In vivo, extensive necrotic death of oxidant-exposed lung macrophages results in the release not only of harmful hydrolytic enzymes to the epithelial lining fluid (ELF) from the interior of disrupted lysosomes [
36] but also of reactive Fe from the same organelle [
2‐
5]. This is probably a major reason behind the increased amounts of reactive ELF-Fe, which subjects the respiratory epithelium to increased oxidative stress [
4,
5], that is also observed in many inflammatory lung diseases [
2,
3].
Analyses of the possible reasons behind the observed susceptibility of lysosomes and cells to an oxidant challenge reveal that the anti-oxidant status of macrophages from transplant recipients without AZM is changed toward a pro-oxidative state. This is probably the result of significantly increased amounts of Fe, which are not sufficiently compensated for by an increase of H-ferritin (Table
2). The amounts of GSH were similar in the macrophages from both the transplant recipient without AZM and the healthy subjects (Table
2). Although we emphasize the increased lysosomal Fe reactivity as the most likely reason for a significantly increased susceptibility of lysosomes in lung transplant macrophages without AZM to oxidative stress, we also notice a significant gender mismatch in the present study (Table
1). A gender dependency for the lysosomal susceptibility to oxidative stress seems unlikely but cannot be ruled out by our current research on lung macrophages.
All lung transplant recipients, without AZM or with AZM, were on prophylaxis treatment with omeprazol against gastro-esophageal reflux. Since this drug is a proton pump inhibitor, theoretically, it has the potential to inhibit AZM-mediated cytoprotection by blocking the lysosomal uptake and accumulation of AZM through alkalinizing the lysosomes [
37,
38]. However, lysosomes of macrophages from transplant recipients with AZM were efficiently stabilized in contrast to the lysosomes of the macrophages without AZM. This finding strongly speaks against this theory and is, in fact, well in line with previous studies of different cell types demonstrating no effect of omeprazol on lysosomes regarding their integrity [
39,
40], activity of lysosomal enzymes [
39,
40] or their acidification [
41].
AZM is known to cause an accumulation of phospholipids and cholesterols inside lysosomes, which is an effect mediated by the interaction with phospholipids and a blockage of phospholipase A1 [
42,
43]. This lysosomal accumulation (
i.e., lysosomal phospholipidosis) has previously been proven to greatly increase the lysosomal resistance to oxidative stress [
44,
45]. All transplant recipients with AZM were on this treatment since at least a month before lung macrophages were harvested and studied. Clearly, this long-term effect by AZM on lysosomes of macrophages from transplant recipients treated with the same drug cannot be ruled out as a significant mechanism behind the protection observed in the present study.
Similar to NH
4Cl, AZM may also decrease the lysosomal pool of Fe by raising the pH inside the acidic vacuome (late endosomes and lysosomes), thus blocking the uptake of Fe from the transferrin-transferrin-receptor complex occurring in the late endosomes [
46] and/or preventing the enzymatic liberation of Fe from Fe-containing organic material accumulating inside the lysosomes [
24,
26,
29,
47]. However, assessment of Prussian-blue stained Fe in the macrophages (
i.e., the Golde index) from transplant recipients with AZM did not indicate that this scenario occurs in vivo. In contrast, the Golde index of macrophages from recipients with AZM tended to be higher, not less, than that of macrophages from recipients without AZM. Moreover, protection of J774 macrophages against oxidative stress was afforded by only a 45-min AZM exposure. It takes many hrs of lysosomal alkalinization to achieve this effect on the lysosomal pool of Fe and its reactivity [
29,
47]. Moreover, a short exposure to AZM (4 hrs) had no significant effect on the cellular content of Fe, GSH and H-ferritin in J774 macrophages. Collectively, these findings do, indeed, suggest a more immediate mode of action by AZM on lysosomes. Importantly, test tube experiments indicate that AZM forms a relatively stable 1:1 complex with Fe
2+[
48]. The lactone ring in the AZM molecule is substituted with a number of hydroxyl and amine functional groups that are positioned in a suitable configuration for interaction with Fe.
H-DFO is a potent chelator of Fe, which exclusively targets the lysosomal pool of Fe [
30]. This is because H-DFO is a high-molecular-weight neutral polymer that cannot be degraded by the lysosomal enzymes, and, thus, remains permanently inside the lysosomal compartment after endocytic uptake [
30]. AZM and H-DFO prevented LMP and cell death to a similar extent (Figure
3 and Figure
4). On a molar basis, AZM was 60 times more efficient than H-DFO. AZM rapidly accumulates inside the cells and lysosomes through a concentration- and pH-dependent passive diffusion [
24‐
26], while the fluid-phase endocytosis of H-DFO is far less effective and a slower process for a lysosomal deposition of drugs. Thus, AZM is lysosomotropic, which has been demonstrated in previous studies on a number of cell types including J774 macrophages [
24‐
26]. In line with these previous findings we demonstrated an almost complete loss of cell protection by AZM in the presence of a brief exposure to NH
4Cl that raised the pH of the lysosomes (Figure
4).
Overall, our findings are consistent with previous research demonstrating a disturbed Fe metabolism in lung transplants [
49‐
51]. However, the present study expands our understanding greatly about how oxidative damage in the lung transplant may be mediated, pointing out the important role of lysosomes. The observations of the present study also indicate that AZM effectively prevents oxidative damage on lysosomes and concomitant cell death. It seems that AZM exerts an immediate effect on a currently unknown lysosomal product that is harmful during an oxidant challenge. We believe that the most likely candidate would be free or loosely bound lysosomal Fe that is in a reactive state, but further studies are warranted.
Competing interests
None of the authors have any conflicts of interest, financial or non-financial, to disclose.
Authors' contributions
HLP designed the study, performed bronchoscopies, wrote the manuscript and obtained grant fundings. LKV performed experiments and wrote parts of the manuscript. MS, JP, SDL and UW contributed to the manuscript writing and MS also performed bronchoscopies. All authors have given their final approval of the version submitted. This study was performed at the Divisions of Pulmonary Medicine and Experimental Pathology, Linköping University, Sweden